Nurix Therapeutics, INC. 8-K Filing

Ticker: NRIX · Form: 8-K · Filed: Dec 9, 2025 · CIK: 1549595

Sentiment: neutral

Filing Stats: 1,791 words · 7 min read · ~6 pages · Grade level 9.8 · Accepted 2025-12-09 06:05:19

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 6, 2025, Nurix Therapeutics, Inc. (the "Company") issued a press release (the "December 6, 2025 press release") announcing the presentation at the 67th American Society of Hematology Annual Meeting and Exposition (the "ASH Annual Meeting") of new clinical data from the Phase 1a/1b study of the Company's novel Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). On December 8, 2025, the Company issued a press release (the "December 8, 2025 press release") announcing the presentation at the ASH Annual Meeting of new clinical data from patients with Waldenstrm macroglobulinemia (WM) treated in the Phase 1 study of bexobrutideg. Also on December 8, 2025, the Company hosted a webcast to review the data presented at the ASH Annual Meeting and provide a corporate update. A copy of the December 6, 2025 press release, the December 8, 2025 press release and the presentation materials for the webcast, which include the data presented at the ASH Annual Meeting, are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibits 99.1, 99.2 and 99.3, shall not be deemed an admission as to the materiality of any information in this

01 Other Events

Item 8.01 Other Events. On December 6, 2025, the Company announced new clinical data from the Phase 1a/1b clinical trial of bexobrutideg (NX-5948) in patients with relapsed or refractory CLL and SLL, and on December 8, 2025, the Company announced new clinical data from patients with relapsed or refractory Waldenstrm macroglobulinemia (WM) treated in the Phase 1 clinical trial of bexobrutideg. Data from Patients with Relapsed or Refractory CLL and SLL The new data from the Phase 1a/1b study of bexobrutideg (NX-5948-301) in patients with relapsed or refractory CLL and SLL include safety findings across all patients, safety findings for patients treated at the recommended Phase 2 dose (RP2D) of 600 mg once daily, updated Phase 1a results with extended follow-up, and emerging efficacy results from the randomized Phase 1b cohort 1 comparing 200 mg and 600 mg once-daily dosing. Phase 1a/1b demographics and safety findings Overall, the heavily pretreated Phase 1a/1b population had received a median of three prior lines of therapy (range = 1–17) including prior Bruton's tyrosine kinase (BTK) inhibitors (85.7%), prior BCL-2 inhibitors (61.9%), and prior non-covalent BTK inhibitors (27.0%). The Phase 1a population had received a median of four prior lines of therapy (range = 2-12) including prior BTK inhibitors (97.9%), prior BCL-2 inhibitors (83.3%), and prior non-covalent BTK inhibitors (27.1%). At baseline, many patients had mutations associated with BTK inhibitor resistance, including mutations in BTK (39.6% overall, 38.3% in the Phase 1a population) and PLCG2 (8.1% overall, 14.9% in the Phase 1a population). Poor prognostic features were common, including TP53 mutations (39.6% overall, 44.7% in the Phase 1a population). Of the five patients (4.0%) in the trial who had central nervous system (CNS) involvement, all five were in the Phase 1a population. Bexobrutideg was well tolerated across all dose levels evaluated, consistent with prior disclosures. The treatment

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith and this list is intended to constitute the exhibit index: Exhibit No. Exhibit Title or Description 99.1 Nurix Therapeutics, Inc. Press Release dated December 6 , 2025 99.2 Nurix Therapeutics, Inc. Press Release dated December 8 , 2025 99.3 Nurix Therapeutics, Inc. Presentation dated December 8, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 4

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. Date: December 9, 2025 By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer 5

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing